Companies › Biopharma Plasma
1 active drug program in 1 registered trial: 1 Phase 3; Immunology; next expected readout Apr 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BP-SCIG 20% Human normal immunoglobulin G (IgG) replacement therapy | – | Phase 3 | Primary Immunodeficiency Diseases | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07346859 | BP-SCIG 20% | Phase 3 | Primary Immunodeficiency Diseases | Immunology | Apr 2028 |
No annotated target.
–
Psoriasis Research Institute of Guangzhou KalVista Pharmaceuticals Triple Hair Infant Bacterial Therapeutics Aresus Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.